Clinical Trial Update: DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating DZD1516 in combination with trastuzumab and capecitabine, or with T-DM1, for metastatic HER2-positive breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• DZD1516
• T-DM1 (ado-trastuzumab emtansine)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Dizal Pharmaceuticals | Conditions: Breast Cancer Metastatic | Phase 1 | Status: COMPLETED